EIF4E and posterior cortical atrophy: Our findings establish for the first time that agents such as NRs, which simultaneously inhibit activation of both AR and eIF4E to suppress growth and progression in genetically diverse PCa cells at pharmacologically feasible concentration, are novel therapeutics for treatment of both androgen-sensitive and castration resistant PCa.